Precision BioSciences, Inc.
302 East Pettigrew Street
Durham
North Carolina
27701
United States
Tel: 919-314-5512
Fax: 480-393-5553
Website: http://www.precisionbiosciences.com/
About Precision BioSciences, Inc.
Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly sophisticated edits for gene insertion and/or gene repair. Precision’s in vivo gene editing pipeline consists of wholly-owned preclinical candidates for primary hyperoxaluria type 1 (PBGENE-PH1), familial hypercholesteremia (PBGENE-PCSK9) and chronic hepatitis B (PBGENE-HBV). It has also partnered with Lilly to develop candidates for Duchenne muscular dystrophy and two other programs targeting the liver and CNS. Precision’s allogeneic CAR T pipeline consists of multiple investigational candidates in early-stage clinical trials, including its first and second generation CD19 targeting candidates PBCAR0191 and PBCAR19B for relapsed and/or refractory (R/R) non-Hodgkin and B-cell lymphoma patients. Precision has also prioritized development of PBCAR269A, its BCMA targeted candidate in combination with a gamma secretase inhibitor for R/R patients with multiple myeloma. Precision BioSciences and its in-house manufacturing facility for AAV, mRNA, and CAR T cells is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com
Stock Symbol: DTIL
Stock Exchange: NASDAQ
Precision BioSciences: Culture
238 articles about Precision BioSciences, Inc.
-
Precision BioSciences Receives Fast Track Designation from U.S. Food and Drug Administration for PBCAR269A, an Investigational Allogeneic CAR T Therapy for Relapsed/Refractory Multiple Myeloma
9/9/2020
Precision BioSciences, Inc. announced the U.S. Food and Drug Administration has granted Fast Track Designation to PBCAR269A for the treatment of relapsed/refractory multiple myeloma.
-
Precision BioSciences to Present at Upcoming Virtual Investor Conferences in September 2020
9/2/2020
Precision BioSciences, Inc., a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, announced its participation in the following upcoming investor conferences:
-
Precision BioSciences Receives Fast Track Disease Designation from U.S. Food and Drug Administration for PBCAR0191 Investigational Allogeneic CAR T Cell Therapy
8/19/2020
Precision BioSciences, Inc. announced the U.S. Food and Drug Administration has granted Fast Track Designation to Precision for PBCAR0191, the company’s lead investigational allogeneic chimeric antigen receptor cell therapy for the treatment of advanced B-cell precursor acute lymphoblastic leukemia.
-
Precision BioSciences Reports Second Quarter 2020 Financial Results and Provides Business Update
8/13/2020
Dosed First Patient in Phase 1/2a Clinical Trial of PBCAR269A, a BCMA-Targeted Allogeneic CAR T Candidate for Multiple Myeloma
-
Precision BioSciences to Report Second Quarter 2020 Financial Results and Present at Upcoming Investor Conferences
8/3/2020
Precision BioSciences, Inc., a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform announced it will report financial results for the second quarter of 2020 on August 13, 2020.
-
Precision BioSciences Regains Rights to In Vivo Hepatitis B Virus Program
7/6/2020
Precision BioSciences, Inc., a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, announced that the Company will regain full rights and all data it generated for the in vivo chronic hepatitis B virus program developed under its 2018 collaboration agreement with Gilead Sciences.
-
Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR269A for Multiple Myeloma
6/8/2020
PBCAR269A Targets BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma and is the Company’s Third Investigational Allogeneic CAR T Candidate Advanced to the Clinic
-
Precision BioSciences to Present at Upcoming Investor Conferences in June 2020
5/26/2020
Precision BioSciences, Inc., a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform announced its participation in the following upcoming investor conferences
-
Precision BioSciences Reports First Quarter 2020 Financial Results and Provides Business Update
5/15/2020
Dosed First Patient in Phase 1/2a Clinical Study of PBCAR20A in Relapsed/Refractory NHL, CLL, and SLL PBCAR0191 Phase 1/2a Trial is Progressing with Updated Interim Data Expected in 2020; Phase 1/2a Trial of PBCAR269A in Patients with Multiple Myeloma Expected to Begin in 2020 Expect to Select Clinical Candidate for in vivo Gene Correction Program Targeting PH1 in 2020 DURHAM, N.C., May 15, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company de
-
Precision BioSciences to Report First Quarter 2020 Financial Results and Present at Bank of America Securities Health Care Conference 2020
5/7/2020
Precision BioSciences, Inc., a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, announced that it will report financial results for the first quarter of 2020 on May 15, 2020.
-
Precision BioSciences Announces Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting
4/28/2020
Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® gene editing platform, today announced that the Company and its collaborators will present at the upcoming American Society of Genetic & Cell Therapy (ASGCT) Annual Meeting held virtually May 12-15, 2020.
-
Precision Biosciences Appoints Dora Alvarado as Senior Vice President of Human Resources
4/15/2020
Precision BioSciences, Inc., a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, announced that Dora Alvarado has joined the leadership team as Senior Vice President, Human Resources.
-
Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR20A for Relapsed/Refractory NHL, CLL, and SLL
4/7/2020
Precision BioSciences, Inc. announced the initiation of patient dosing in a Phase 1/2a clinical trial of its second off-the-shelf chimeric antigen receptor T cell therapy candidate, PBCAR20A.
-
Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germano
3/11/2020
Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, announced today that Geno Germano, President and CEO of Elucida Oncology, has been appointed to the company’s Board of Directors.
-
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update
3/10/2020
Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, today announced financial results for the fourth quarter and fiscal year ended December 31, 2019, and provided a business update.
-
Precision BioSciences to Report Fiscal Year and Fourth Quarter 2019 Financial Results and Present at Upcoming Investor Conferences
2/21/2020
Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, announced today that it will publish financial results for the fiscal year and fourth quarter of 2019 and provide a corporate update on March 10, 2020.
-
Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma
1/13/2020
Phase 1 clinical trial of off-the-shelf (allogeneic) anti-BCMA CAR T therapy candidate for patients with relapsed/refractory multiple myeloma expected to begin dosing patients in 2020
-
Precision BioSciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/6/2020
Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced that Matt Kane, co-founder and CEO, will present at the 38th Annual J.P. Morgan Healthcare Conference
-
Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting from Relapsed / Refractory NHL and B-ALL Patients Treated at Dose Levels 1 & 2 in the Ongoing Phase 1/2a Clinical Trial of PBCAR0191
12/9/2019
PBCAR0191 continues to be associated with no serious adverse events or dose limiting toxicities observed to date, and no cases of graft-versus-host disease
-
Precision BioSciences Welcomes Healthcare Industry Expert, Kevin J. Buehler, to its Board of Directors
11/13/2019
Precision BioSciences, Inc., a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, announced that Kevin J. Buehler, former CEO of Alcon Laboratories, has been appointed to its Board of Directors, which took effect following the company’s third quarter board meeting held on November 8, 2019..